A new era of HIV prevention is upon us. Pharmaceutical company Gilead Sciences Canada recently announced it is seeking approval from Health Canada for the use of Truvada as Pre-Exposure Prophylaxis. Better known as PrEP, the new highly effective prevention tool is now on track to be available in Canada.
John Maxwell is the Executive Director of ACT. John has been working in the community-based HIV/AIDS sector for over 25 years. He has extensive experience in the area of HIV prevention and sexual health promotion, and has been an active participant in many community-based research projects. John has also been a member of numerous local, provincial and national and international HIV/AIDS working groups.
As a result of the stigma around HIV, many folks feel shame and judgment about how they got HIV and don't want others finding out. We believe that isolation is alleviated by networks of support, by the opportunity to create shared experiences with other people, by the opportunity to be true to who you are without fear.
08/04/2015 05:12 EDT
The full spectrum of how the HIV epidemic has impacted women in Ontario is a relatively new topic. This is, of course, despite women having been affected by HIV since the beginning. These are some of the challenges that face the women who live with or are at risk for HIV. They are manifold and they are ingrained, but they are not insurmountable.
03/21/2015 11:36 EDT
SUBSCRIBE AND FOLLOW